• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无表面活性剂的 BCS 类 IV 药物固体分散体在无定形壳寡糖基质中的应用,可同时提高体外溶解 - 渗透性能。

Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase.

机构信息

School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of TCM, Nanjing 210023, China.

Key Lab of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.

出版信息

Eur J Pharm Sci. 2019 Mar 15;130:147-155. doi: 10.1016/j.ejps.2019.01.031. Epub 2019 Jan 27.

DOI:10.1016/j.ejps.2019.01.031
PMID:30699368
Abstract

Saccharides have been applied as a water-soluble matrix for dispersing hydrophobic drugs homogeneously without the need to use surfactants in amorphous solid dispersions (ASD). Up to now, concomitant permeability improvement of BCS Class IV drug by such matrices have not been much appreciated. Herein, an amorphous chitosan oligosaccharide (COS) was used as matrix to prepare surfactant-free ASD of BCS class IV drug by the ball milling method, with curcumin (CUR) as a model drug. The DSC, XRPD, FTIR and physical stability experiments indicated that CUR was in an amorphous state with high physical stability and exhibited potential interactions with COS in the ASD. Non-sink dissolution in vitro studies showed the maximum dissolution concentration of all CUR-COS ASD (CUR and COS at weight ratios of 1:1, 1:2 and 1:4) reached ranging from 97.85 to 101.21 μg/mL, far above that of pure CUR. The supersaturated concentration remained for at least 24 h under non-sink condition. Caco-2 cell model revealed that, compared to the pure CUR group, the apparent permeability coefficients were increased by 1.72-4.44-fold in all three CUR-COS ASD, which was mainly attributed to opening the tight junctions of Caco-2 cells by COS. The pharmacokinetic study showed that all CUR-COS ASD groups exhibited significant enhancements in AUC, with 1.55-3.01-fold that of pure CUR (p < 0.01). T of CUR was shortened after oral administration of all three ASD. The current study demonstrates the amorphous COS could be used as a promising matrix in ASD for enhancing the oral bioavailability of BCS class IV drug by improving dissolution behavior and membrane permeability.

摘要

糖类已被应用于作为水溶性基质,用于均匀分散亲脂性药物,而无需在无定形固体分散体(ASD)中使用表面活性剂。到目前为止,这种基质对 BCS 类 IV 药物的同时渗透性改善还没有得到太多的重视。本文中,我们使用无定形壳寡糖(COS)作为基质,通过球磨法制备了 BCS 类 IV 药物的无表面活性剂 ASD,以姜黄素(CUR)为模型药物。DSC、XRPD、FTIR 和物理稳定性实验表明,CUR 处于无定形状态,具有较高的物理稳定性,并在 ASD 中与 COS 表现出潜在的相互作用。非溶出度体外研究表明,所有 CUR-COS ASD(CUR 和 COS 重量比为 1:1、1:2 和 1:4)的最大溶解浓度均达到 97.85-101.21μg/mL,远高于纯 CUR。在非溶出条件下,过饱和浓度至少保持 24 小时。Caco-2 细胞模型表明,与纯 CUR 组相比,所有 CUR-COS ASD 的表观渗透系数均增加了 1.72-4.44 倍,这主要归因于 COS 打开了 Caco-2 细胞的紧密连接。药代动力学研究表明,所有 CUR-COS ASD 组的 AUC 均显著增加,与纯 CUR 相比增加了 1.55-3.01 倍(p<0.01)。CUR 的 T 在用所有三种 ASD 口服给药后缩短。本研究表明,无定形 COS 可用作 ASD 中的一种有前途的基质,通过改善溶解行为和膜通透性来提高 BCS 类 IV 药物的口服生物利用度。

相似文献

1
Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase.无表面活性剂的 BCS 类 IV 药物固体分散体在无定形壳寡糖基质中的应用,可同时提高体外溶解 - 渗透性能。
Eur J Pharm Sci. 2019 Mar 15;130:147-155. doi: 10.1016/j.ejps.2019.01.031. Epub 2019 Jan 27.
2
Surfactant-free amorphous solid dispersion with high dissolution for bioavailability enhancement of hydrophobic drugs: a case of quercetin.无表面活性剂的高溶解性无定形固体分散体提高疏水性药物生物利用度:以槲皮素为例。
Drug Dev Ind Pharm. 2021 Jan;47(1):153-162. doi: 10.1080/03639045.2020.1862173.
3
Improved Oral Absorption of Poorly Soluble Curcumin via the Concomitant Use of Borneol.通过同时使用冰片提高难溶性姜黄素的口服吸收。
AAPS PharmSciTech. 2019 Mar 22;20(4):150. doi: 10.1208/s12249-019-1364-5.
4
Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine.在无赋形剂固体分散体中与胡椒碱共同形成时,代谢-通透性的参与增强了姜黄素的口服生物利用度。
Int J Pharm. 2019 Apr 20;561:9-18. doi: 10.1016/j.ijpharm.2019.02.027. Epub 2019 Feb 25.
5
Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.具有改善溶出度和生物利用度的鸢尾黄素固体分散体的制备、表征及体内外评价
Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):413-22. doi: 10.1007/s13318-015-0265-6. Epub 2015 Feb 11.
6
[Effect of HPMCAS/curcumin amorphous solid dispersion in enhancing dissolution and chemical stability of curcumin].[羟丙基甲基纤维素醋酸琥珀酸酯/姜黄素无定形固体分散体对提高姜黄素溶出度和化学稳定性的作用]
Zhongguo Zhong Yao Za Zhi. 2019 Aug;44(15):3305-3311. doi: 10.19540/j.cnki.cjcmm.20190516.301.
7
Improved bioavailability and antiasthmatic efficacy of poorly soluble curcumin-solid dispersion granules obtained using fluid bed granulation.采用流化床制粒法制备的难溶性姜黄素固体分散体颗粒,其生物利用度和抗哮喘疗效得到改善。
Biomed Mater Eng. 2014;24(1):413-29. doi: 10.3233/BME-130826.
8
Effects of chitosan molecular weight on the physical and dissolution characteristics of amorphous curcumin-chitosan nanoparticle complex.壳聚糖分子量对无定形姜黄素-壳聚糖纳米颗粒复合物物理及溶解特性的影响
Drug Dev Ind Pharm. 2018 Jan;44(1):82-88. doi: 10.1080/03639045.2017.1373802. Epub 2017 Sep 11.
9
Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.制备无定形呋塞米钠盐可提高溶解度和溶出速率,并导致大鼠口服给药后的 Tmax 更快。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):942-51. doi: 10.1016/j.ejpb.2013.09.002. Epub 2013 Sep 27.
10
Enhancement of Oral Bioavailability of Curcumin by a Novel Solid Dispersion System.一种新型固体分散体系统提高姜黄素的口服生物利用度
AAPS PharmSciTech. 2015 Dec;16(6):1327-34. doi: 10.1208/s12249-014-0254-0. Epub 2015 Mar 25.

引用本文的文献

1
Biocompatible Natural Polymer-Based Amorphous Solid Dispersion System Improving Drug Physicochemical Properties, Stability, and Efficacy.基于生物相容性天然聚合物的无定形固体分散体系统改善药物的物理化学性质、稳定性和疗效。
Polymers (Basel). 2025 Jul 28;17(15):2059. doi: 10.3390/polym17152059.
2
Investigation of Stabilized Amorphous Solid Dispersions to Improve Oral Olaparib Absorption.用于改善奥拉帕利口服吸收的稳定化无定形固体分散体的研究
Pharmaceutics. 2024 Jul 19;16(7):958. doi: 10.3390/pharmaceutics16070958.
3
Preparation and Characterization of Lutein Co-Amorphous Formulation with Enhanced Solubility and Dissolution.
具有增强溶解度和溶出度的叶黄素共无定形制剂的制备与表征
Foods. 2024 Jun 26;13(13):2029. doi: 10.3390/foods13132029.
4
Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review.氨基酸对低溶性药物进行非晶化以提高其治疗效果:综述。
AAPS PharmSciTech. 2023 Dec 7;24(8):253. doi: 10.1208/s12249-023-02709-2.
5
Recent Advances in Enhancement of Dissolution and Supersaturation of Poorly Water-Soluble Drug in Amorphous Pharmaceutical Solids: A Review.近年来改善非水溶性药物在无定形药物固体中溶解和过饱和的进展:综述。
AAPS PharmSciTech. 2021 Dec 10;23(1):16. doi: 10.1208/s12249-021-02137-0.
6
Deaggregation and Crystallization Inhibition by Small Amount of Polymer Addition for a Co-Amorphous Curcumin-Magnolol System.少量聚合物添加对姜黄素-厚朴酚共无定形体系的解聚和结晶抑制作用
Pharmaceutics. 2021 Oct 18;13(10):1725. doi: 10.3390/pharmaceutics13101725.
7
The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability.功能性辅料在固体口服制剂中对克服药物溶出度差和生物利用度低的作用。
Pharmaceutics. 2020 Apr 25;12(5):393. doi: 10.3390/pharmaceutics12050393.
8
Mechanisms of increased bioavailability through amorphous solid dispersions: a review.通过无定形固体分散体增加生物利用度的机制:综述。
Drug Deliv. 2020 Dec;27(1):110-127. doi: 10.1080/10717544.2019.1704940.